| Characteristics |
MAC (n = 46) |
RIC (n = 47) |
p-value |
| Diagnosis: |
| AML |
46 |
47 |
|
| Favorable cytogenetics/intermed/adverse |
5/28/2009 |
2/33/11 |
ns |
| Disease stage (CR1/ > CR2) |
28/18 |
22/25 |
ns |
| Sex (M/F) |
28/18 |
23/24 |
ns |
| Age |
39 (21–59) |
59 (31–69) |
< 0.001 |
| Donor: |
|
|
0.06 |
| Sibling |
22 |
13 |
|
| MUD |
21 |
30 |
|
| Allele MM MUD |
3 |
4 |
|
| Donor sex (M/F) |
26/19 |
29/18 |
ns |
| Donor age |
37 (18–66) |
34 (20–71) |
ns |
| Female to male |
9 |
3 |
0.07 |
| Stem cell source (BM/PBSCs) |
Apr-42 |
May-42 |
ns |
| NC dose (×106/kg) |
11.1 (1.5–28.8) |
11.3 (2.3–32.7) |
ns |
| CD34 dose (×106/kg) |
7.7 (0.2–25.5) |
6.9 (0.6–18.1) |
ns |
| GVHD prophylaxis: |
| CsA + MTX |
42 |
42 |
|
| CsA + MMF |
0 |
1 |
|
| Tacrolimus + Sirolimus |
4 |
4 |
|
| Conditioning: |
| Busulfan-based |
40 |
41 |
|
| TBI-based |
4 |
0 |
|
| Chemo-based |
0 |
6* |
|
| +ATG |
24 (52%) |
41 (87%) |
< 0.001 |
| *Fu + Cy: n = 1; Flu + Treo: n = 5. |
|
|
| Abbreviations: AML = Acute Myeloid Leukemia; CR1 = Complete Remission; M = Male; F = Female; MUD=Matched Unrelated Donor; MM = Mismatch; BM= Bone Marrow; PBSCs = Peripheral Blood Stem Cells; NC dose = Nucleated Cell dose; CsA = Cyclosporine; MTX = Methotrexate; MMF = Mycophenolate mofetil; TBI = Total Body Irradiation; ATG = Antithymocyte Globulin. |
